If, using conservative estimates, even one-third of a cross-section of the population over 65–70 years of age have amyloid and tau deposits in their brain, using amyloid β and p-tau blood biomarkers for early detection of AD and treatment may place a colossal burden on health care services without benefit in most. This evidence concerns the gene MAPT and Alzheimer disease.